-

Agilent’s MMR IHC Panel pharmDx (Dako Omnis) Receives European IVDR Certification as a Companion Diagnostic Test for Colorectal Cancer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.

The MMR pathway corrects DNA replication errors to maintain genomic stability2. Dysfunction in key MMR proteins (MLH1, PMS2, MSH2, and MSH6) causes MMR deficiency (dMMR), leading to elevated mutations, tumorigenesis, and neoantigen accumulation—features that make dMMR tumors more responsive to immunotherapy due to enhanced immune recognition3.

MMR IHC Panel pharmDx (Dako Omnis) is an immunohistochemical panel specifically developed and validated to detect the loss of function of any of the four MMR proteins in formalin-fixed paraffin-embedded colorectal cancer tissue. Agilent’s panel is the only companion diagnostic IHC panel IVDR approved to diagnose colorectal cancer patients eligible for treatment with OPDIVO® in combination with YERVOY®.

Nina Green, vice-president and general manager of Agilent’s Clinical Diagnostics Division remarked: “The approval of MMR IHC Panel pharmDx will provide physicians in Europe with critical information to inform treatment decisions for patients with mismatch repair deficiency (dMMR). This endorsement underscores Agilent’s leadership in the development of companion diagnostics for groundbreaking therapies.”

Agilent collaborated with Bristol Myers Squibb Company to develop the MMR IHC Panel pharmDx (Dako Omnis).

OPDIVO® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company.

  1. In Vitro Diagnostic Medical Devices Regulation (europa.eu)
  2. Olave, M.C.; Graham, R.P. Mismatch repair deficiency: The what, how, and why it is important. Genes Chromosomes Cancer 2022, 61 (6), 314-321. DOI:10.1002/gcc.23015.
  3. Mulet-Margalef, N.; Linares, J.; Badia-Ramentol, J.; Jimeno, M.; Sanz Monte, C.; Manzano Mozo, J.L.; Calon, A. Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape. Cancers 2023, 15 (4), 1022. DOI: 10.3390/cancers15041022. PMID: 36831367; PMCID: PMC9954007.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

Industry:

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB
Release Versions
English

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC...

Agilent Showcases Next‑Generation Automated Solutions at SLAS2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it will present a range of next‑generation automated workflow innovations at the SLAS2026 International Conference & Exhibition, taking place February 7–11 in Boston, Massachusetts. Agilent will demonstrate how its expanding automation ecosystem—integrating advanced imaging, software, robotics, and AI‑powered optimization—supports laboratories in accelerating discovery with confidence, efficiency,...
Back to Newsroom